BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24638984)

  • 1. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.
    Giannelli G; Villa E; Lahn M
    Cancer Res; 2014 Apr; 74(7):1890-4. PubMed ID: 24638984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
    Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
    Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
    Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
    Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel method in order to evaluate the efficacies and the safeties of new drugs for hepatocellular carcinoma with loss of transforming growth factor-beta signaling.
    Moriguchi H
    Hepatology; 2009 Dec; 50(6):2050-1; author reply 2051. PubMed ID: 19937676
    [No Abstract]   [Full Text] [Related]  

  • 5. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
    Mazzocca A; Fransvea E; Dituri F; Lupo L; Antonaci S; Giannelli G
    Hepatology; 2010 Feb; 51(2):523-34. PubMed ID: 19821534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis.
    Yamazaki K; Masugi Y; Sakamoto M
    Dig Dis; 2011; 29(3):284-8. PubMed ID: 21829019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of interferon regulatory factor 1 and S100C/A11 in growth inhibition by transforming growth factor beta 1 in human hepatocellular carcinoma cells.
    Miyazaki M; Sakaguchi M; Akiyama I; Sakaguchi Y; Nagamori S; Huh NH
    Cancer Res; 2004 Jun; 64(12):4155-61. PubMed ID: 15205326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes.
    Gotzmann J; Fischer AN; Zojer M; Mikula M; Proell V; Huber H; Jechlinger M; Waerner T; Weith A; Beug H; Mikulits W
    Oncogene; 2006 May; 25(22):3170-85. PubMed ID: 16607286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells.
    Bertran E; Crosas-Molist E; Sancho P; Caja L; Lopez-Luque J; Navarro E; Egea G; Lastra R; Serrano T; Ramos E; Fabregat I
    Hepatology; 2013 Dec; 58(6):2032-44. PubMed ID: 23813475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale for targeting TGF-β in chronic liver diseases.
    Giannelli G; Mikulits W; Dooley S; Fabregat I; Moustakas A; ten Dijke P; Portincasa P; Winter P; Janssen R; Leporatti S; Herrera B; Sanchez A
    Eur J Clin Invest; 2016 Apr; 46(4):349-61. PubMed ID: 26823073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
    Chung CL; Wang SW; Sun WC; Shu CW; Kao YC; Shiao MS; Chen CL
    Biochem Pharmacol; 2018 Aug; 154():39-53. PubMed ID: 29678520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of smads in its growth.
    Matsuzaki K; Date M; Furukawa F; Tahashi Y; Matsushita M; Sugano Y; Yamashiki N; Nakagawa T; Seki T; Nishizawa M; Fujisawa J; Inoue K
    Hepatology; 2000 Aug; 32(2):218-27. PubMed ID: 10915727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β signaling in onset and progression of hepatocellular carcinoma.
    Meindl-Beinker NM; Matsuzaki K; Dooley S
    Dig Dis; 2012; 30(5):514-23. PubMed ID: 23108308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β signaling and epithelial-mesenchymal transition in cancer progression.
    Katsuno Y; Lamouille S; Derynck R
    Curr Opin Oncol; 2013 Jan; 25(1):76-84. PubMed ID: 23197193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting TGF-β signaling in hepatocellular carcinoma.
    Giannelli G; Mazzocca A; Fransvea E; Lahn M; Antonaci S
    Biochim Biophys Acta; 2011 Apr; 1815(2):214-23. PubMed ID: 21129443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition.
    Tanahashi T; Osada S; Yamada A; Kato J; Yawata K; Mori R; Imai H; Sasaki Y; Saito S; Tanaka Y; Nonaka K; Yoshida K
    Int J Oncol; 2013 Feb; 42(2):556-64. PubMed ID: 23229794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition.
    Lacher MD; Tiirikainen MI; Saunier EF; Christian C; Anders M; Oft M; Balmain A; Akhurst RJ; Korn WM
    Cancer Res; 2006 Feb; 66(3):1648-57. PubMed ID: 16452224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules.
    Paik SY; Park YN; Kim H; Park C
    Mod Pathol; 2003 Jan; 16(1):86-96. PubMed ID: 12527718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of transforming growth factor-beta 1 in hepatocellular carcinoma in comparison with the non-tumor tissue.
    Idobe Y; Murawaki Y; Kitamura Y; Kawasaki H
    Hepatogastroenterology; 2003; 50(49):54-9. PubMed ID: 12629989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
    J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.